Alpha Teknova, Inc. (TKNO) stock
TKNONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/30144% above fair value
$8.29−0.32 (-3.77%)
Close on Nov 12, 2026Market cap $445.34MP/E –Yield –
Alpha Teknova r&d expenses
Research and development expenses are spending on new products and technology.
Alpha Teknova's R&D Expenses for the twelve months ending Sep 30, 2026 was $2.27M, down 0.1% year over year. For fiscal 2025 it was $2.20M, down 20.4% from the year before. The highest annual figure on record is $7.74M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.20M | -20.4% |
| FY2024 | Dec 31, 2024 | $2.76M | -50.4% |
| FY2023 | Dec 31, 2023 | $5.57M | -28.0% |
| FY2022 | Dec 31, 2022 | $7.74M | +79.4% |
| FY2021 | Dec 31, 2021 | $4.31M | +186.1% |
| FY2020 | Dec 31, 2020 | $1.51M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $581.00K | +7.2% |
| Q2 FY2026 | Jun 30, 2026 | $554.00K | -4.6% |
| Q1 FY2026 | Mar 31, 2026 | $609.00K | +10.3% |
| Q4 FY2025 | Dec 31, 2025 | $522.00K | -12.1% |
| Q3 FY2025 | Sep 30, 2025 | $542.00K | -13.6% |
| Q2 FY2025 | Jun 30, 2025 | $581.00K | -14.3% |
| Q1 FY2025 | Mar 31, 2025 | $552.00K | -35.8% |
| Q4 FY2024 | Dec 31, 2024 | $594.00K | -54.7% |
| Q3 FY2024 | Sep 30, 2024 | $627.00K | -55.1% |
| Q2 FY2024 | Jun 30, 2024 | $678.00K | -53.7% |
| Q1 FY2024 | Mar 31, 2024 | $860.00K | -38.4% |
| Q4 FY2023 | Dec 31, 2023 | $1.31M | -29.9% |
| Q3 FY2023 | Sep 30, 2023 | $1.40M | -27.4% |
| Q2 FY2023 | Jun 30, 2023 | $1.46M | -24.1% |
| Q1 FY2023 | Mar 31, 2023 | $1.40M | -30.7% |
| Q4 FY2022 | Dec 31, 2022 | $1.87M | +34.5% |
| Q3 FY2022 | Sep 30, 2022 | $1.93M | +40.3% |
| Q2 FY2022 | Jun 30, 2022 | $1.93M | +126.7% |
| Q1 FY2022 | Mar 31, 2022 | $2.01M | +187.6% |
| Q4 FY2021 | Dec 31, 2021 | $1.39M | +188.4% |
| Q3 FY2021 | Sep 30, 2021 | $1.37M | +283.2% |
| Q2 FY2021 | Jun 30, 2021 | $851.00K | +149.6% |
| Q1 FY2021 | Mar 31, 2021 | $700.00K | – |
| Q4 FY2020 | Dec 31, 2020 | $482.00K | – |
| Q3 FY2020 | Sep 30, 2020 | $358.00K | – |
| Q2 FY2020 | Jun 30, 2020 | $341.00K | – |
See a number that looks wrong?